Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.
Sousa
A B
AB
Serviço de Hematologia, Hospital dos Capuchos, Lisboa, Portugal.
Fernandes
J P
JP
Costa
I
I
Ferreira
G
G
Nunes
O
O
Ribeiro
P
P
Neves
A
A
Cruz
E
E
Aveiro
F
F
Rodrigues
A S
AS
Bernardo
M
M
Conduto
A
A
Gonçalves
A J
AJ
Monteiro
A
A
Sousa
M
M
Soares
V H
VH
Veiga
J
J
Gouveia
J
J
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction / Q000379:methods*; D015996:Survival Rate
D003561:Cytarabine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008942:Mitoxantrone